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Diagnostic capability was determined by calculating the area 
under the curve (AUC) in the receiver operating 
characteristic (ROC) curves. This parameter had an AUC value 
of 0.786. It was predictive of G2-G3 complications with 71.4% 
specificity and 72.2% sensibility for a dose difference 
threshold of 48 Gy. 
 
Conclusion: A non-homogenous dose region around urethra at 
the end of the real-time implant is a risk factor for 
development of urethral morbidity.  
Several studies have found dosimetry correlations between 
CT post-plan and urinary morbidity. This study focuses on US 
real-time dosimetry parameters. It allows us to consider new 
constraints and dosimetry alerts during treatment planning.  
A prospective study is under consideration, where a new 
constraint of a 40-50 Gy maximum dose difference around a 
2.5-mm expansion of the urethra will be implemented if 
feasible. 
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Purpose or Objective: The PSA level after definitive 
treatment using radiotherapy decreases but still remains 
detectable. The aim of this study is to analyze clinical and 
dosimetric factors which influence the PSA level in the blood 
serum of patients with prostate cancer after HDR (High Dose 
Rate) brachytherapy. 
 
Material and Methods: 53 patients after HDR brachytherapy 
were qualified to the study from June 2008 to December 
2010. The patients were from T1c to T2c , iPSA from 1.5 to 
19.6 ng / ml with prostate adenocarcinoma (Gleason Scale < 
7) and belonged to the low and intermediate risk of 
recurrence. 20 patients had androgen deprivation therapy. 
Patients were treated with HDR brachytherapy 3 x 15 Gy or 3 
x 10.5 Gy. Median follow-up was 3 years. The PSA Bounce 
threshold was >0.2 ng/ml and the biochemical failure 
definition was nadir PSA +2.0 ng/ml. The influences of 
clinical and dosimetric parameters were assessed . Statistical 
analysis was performed assuming significance level p < 0.05. 
 
Results: PSA Bounce occurred in 22% after average 10.7 
months. The time to PSA increase in BF group after 
brachytherapy HDR was 36 months. It was observed that 
patients with PSA nadir below 0.1 ng/ml were more likely to 
have normal follow-up than PSA Bounce, biochemical failure 
(BF), clinical failure (CF). The amplitude of the PSA increases 
were significantly different between subgroups. The further 
analysis demonstrated only a significant difference between 
the subgroup HDR_Bounce (median 0.7 ng/ml) and HDR_BF 
(median 2.6 ng/ml). The time to PSA increase was 
significantly different between the subgroups of the group 
HDR. It applies to patients with PSA Bounce (median 10.5 
months) and biochemical failure (median 36 months). The 
analysis of others dosimetric and clinical factors (including 
hormonotherapy) didn’t show any significant effect on the 
studied HDR subgroups. 
 
Conclusion: The percentage of patients who had a PSA 
Bounce was 22%. Predisposing factors for PSA Bounce after 
HDR brachytherapy were nadir PSA (median> 0.1 ng / ml) and 
time to PSA increase (median <12 months). There was no 
influence of other analyzed clinical, dosimetric factors and 
use of hormone therapy to occurrence of the PSA Bounce. 
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Purpose or Objective: To evaluate evolution and average 
time to IPSS (International Prostate Symptom Score) 
recovery, in patients who have been submitted to I-125 
prostate brachytherapy (Low dose rate brachytherapy). 
 
Material and Methods: Between March 2011 and December 
2013 we performed 66 prostate brachytherapy in patients 
with low / intermediate risk prostate cancer. 4 patients also 
received external radiotherapy. 14 patients received previous 
hormone therapy. A 145 Gy dose was prescribed if exclusive 
brachytherapy was given and 108 Gy if combined with 
external radiotherapy. All patients were treated with 
Quicklink Delivery System® (BARD) and real-time 
planification. Of the 66 treated patients 5 did not have initial 
IPSS, 13 did not have complete follow up, and the 48 
remaining have a suitable follow up. The variables that have 
been evaluated were: Prostate volume, Qmax, number of 
implanted seeds, number of needles and Urethra´s D1; “p 
value” was obtained from Mann-Whitney test. The prostate 
average volume was 33.73 cc, Qmax: 18.7 ml/sec, number of 
seeds: 60.2, number of needles: 16.1 and urethra`s D1: 138% 
to the prescribed dose. 
 
Results: With an average follow up of 27 months, 41 of 48 
patients (85.4%) recovered their IPSS, with an average 
recovery time of 9 months. 7 patients (15%) showed 
progressive worsening without recovery, and 3 (4.5%) of them 
developed acute urinary retention (AUR) one month after the 
implant. In a multivariate analysis the main factor that 
influenced AUR was the prostate volume, with p= 0.0583, (in 
these 3 patients prostate volume average was 42.47 cc, 
higher than the average non AUR) and other factors that 
seem to influence were IPSS and Qmax values, without 
statistical significance ("p" value) (In these patients Qmax 
average was 7.63 and IPSS average was 9.33, worse than non 
AUR). 
 
Conclusion: 85% of patients with complete follow-up, 
recovered its basal IPSS. The average time to recovery was 9 
months, and the incidence of acute urinary retention was 
lower than 4.5%.  
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